NRX Pharmaceuticals NRXP
NASDAQ NRXP
$2.40 -0.23 (-8.75%)
At close: Oct 22, 2026 · 4:00 PM EDT

NRX Pharmaceuticals (NRXP) EBITDA Margin (2020 - 2026)

Updated

NRX Pharmaceuticals (NRXP) recorded EBITDA Margin of -584.38% in Q2 2026, down 159.01 percentage points from the prior quarter.

Analysis

NRX Pharmaceuticals (NRXP) EBITDA Margin (2020 - 2026) Analysis & Trends

On a TTM basis, NRX Pharmaceuticals' EBITDA Margin came in at -574.81% as of Jun 30, 2026; for FY2025, it came in at -1318.69%.

  • Quarterly EBITDA Margin has ranged from -1652.07% in Q3 2025 to -425.36% in Q1 2026 over the past five years.
  • Per Business Quant, the preceding three quarters came in at -425.36% (Q1 2026), -466.12% (Q4 2025) and -1652.07% (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin (Qtr)
1 Eli Lilly 1,230.11 Bn 1,198.70 Bn 19.71 Bn 53.49%
2 Johnson & Johnson 644.39 Bn 564.25 Bn 17.30 Bn 32.68%
3 AbbVie 503.52 Bn 476.68 Bn 12.70 Bn 49.01%
4 Merck 363.29 Bn 317.72 Bn 12.21 Bn 6.02%
5 Novartis Ag 298.23 Bn 262.62 Bn 11.24 Bn -
6 Astrazeneca 267.53 Bn 241.29 Bn 12.86 Bn 33.11%
7 Amgen 241.80 Bn 197.20 Bn 7.24 Bn 46.01%
8 Gilead Sciences 195.07 Bn 169.19 Bn 6.22 Bn -124.26%
9 Pfizer 173.33 Bn 120.28 Bn 10.94 Bn 39.16%
10 NRX Pharmaceuticals 103.58 Mn 55.17 Mn 426,000.00 -584.38%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -584.38%
Mar 31, 2026 -425.36%
Dec 31, 2025 -466.12%
Sep 30, 2025 -1,652.07%
Dec 31, 2020 -40,649,749.55%
API Access

NRX Pharmaceuticals EBITDA Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebitda-margin&ticker=NRXP&period=max&api_key=YOUR_API_KEY